New drug trial targets Tough-to-Treat breast cancer in the brain

NCT ID NCT04739761

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing an existing drug, trastuzumab deruxtecan, in people with advanced HER2-positive breast cancer that has progressed after prior treatments. It specifically aims to see how well the drug works in two groups: those with and without cancer that has spread to the brain (brain metastases). The main goals are to measure tumor shrinkage and how long patients live without their cancer getting worse.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Boston, Massachusetts, 02215, United States
Research Site

Durham, North Carolina, 27710, United States
Research Site

Adelaide, 5000, Australia
Research Site

Auchenflower, 4066, Australia
Research Site

Clayton, 3168, Australia
Research Site

Heidelberg, 3084, Australia
Research Site

St Leonards, 2065, Australia
Research Site

Subiaco, 6008, Australia
Research Site

Anderlecht, 1070, Belgium
Research Site

Bruges, 8000, Belgium
Research Site

Leuven, 3000, Belgium
Research Site

Liège, 4000, Belgium
Research Site

Vancouver, British Columbia, V5Z 1H7, Canada
Research Site

Toronto, Ontario, M4N 3M5, Canada
Research Site

Copenhagen, 2100, Denmark
Research Site

Herlev, 2730, Denmark
Research Site

Odense C, 5000, Denmark
Research Site

Helsinki, 00290, Finland
Research Site

Tampere, FI-33521, Finland
Research Site

Turku, 20520, Finland
Research Site

Berlin, 13125, Germany
Research Site

Dresden, 1307, Germany
Research Site

Erlangen, 91054, Germany
Research Site

Essen, 45136, Germany
Research Site

Frankfurt, 60389, Germany
Research Site

Hamburg, 20246, Germany
Research Site

Hanover, 30625, Germany
Research Site

Kiel, 24105, Germany
Research Site

Mannheim, 68167, Germany
Research Site

München, 80336, Germany
Research Site

München, 80637, Germany
Research Site

Münster, 48149, Germany
Research Site

Tübingen, 72076, Germany
Research Site

Cork, T12 DV56, Ireland
Research Site

Dublin, 7, Ireland
Research Site

Dublin, D04 Y8V0, Ireland
Research Site

Ancona, 60122, Italy
Research Site

Bergamo, 24127, Italy
Research Site

Catania, 95126, Italy
Research Site

Milan, 20132, Italy
Research Site

Naples, 80131, Italy
Research Site

Padua, 35128, Italy
Research Site

Prato, 59100, Italy
Research Site

Isehara, 259-1193, Japan
Research Site

Kawasaki-shi, 216-8511, Japan
Research Site

Sapporo, 003-0804, Japan
Research Site

Shinagawa-ku, 142-8666, Japan
Research Site

Yokohama, 241-8515, Japan
Research Site

Maastricht, 6229 HX, Netherlands
Research Site

The Hague, 2545 AA, Netherlands
Research Site

Bergen, 5009, Norway
Research Site

Oslo, 450, Norway
Research Site

Oslo, N-0379, Norway
Research Site

Gdansk, 80-214, Poland
Research Site

Krakow, 31-501, Poland
Research Site

Opole, 45-060, Poland
Research Site

Warsaw, 02-781, Poland
Research Site

Warsaw, 04-141, Poland
Research Site

Lisbon, 1400-048, Portugal
Research Site

Lisbon, 1649-035, Portugal
Research Site

Porto, 4099-001, Portugal
Research Site

Barcelona, 08036, Spain
Research Site

Barcelona, 8035, Spain
Research Site

Bilbao (Vizcaya), 48013, Spain
Research Site

Granada, 18014, Spain
Research Site

Madrid, 28005, Spain
Research Site

Madrid, 28034, Spain
Research Site

Madrid, 28041, Spain
Research Site

Salamanca, 37007, Spain
Research Site

Santander, 39008, Spain
Research Site

Santiago de Compostela-Coruña, 15706, Spain
Research Site

Seville, 41013, Spain
Research Site

Valencia, 46009, Spain
Research Site

Gothenburg, 413 45, Sweden
Research Site

Lund, 221 85, Sweden
Research Site

Uppsala, 751 85, Sweden
Research Site

Basel, 4031, Switzerland
Research Site

Bellinzona, CH-6500, Switzerland
Research Site

Lausanne, 1011, Switzerland
Research Site

Lucerne, 6000, Switzerland
Research Site

Edinburgh, EH4 2XR, United Kingdom

Conditions

Explore the condition pages connected to this study.

BREAST CANCER